Apr 20,2014

Welby Inc. announced that it has received funding from Dentsu Innovation Partners Inc.

Welby Inc. announced that it has received a round of funding from new investor Dentsu Digital Investment Business Limited Partnership, a fund managed by Dentsu Innovation Partners Inc. on April 21, 2014. The company issued shares by third-party allocation to the investor.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Dec 18,2020

Voluntis obtains €3 million of additional non-dilutive loans and optimizes its existing financing

Voluntis, a leader in the field of digital therapeutics, announces that it has been granted new state-guaranteed loans (Prêt Garanti par l’Etat, or PGE in France) for a total amount of €3 million from BNP Paribas and Crédit du Nord and the optimization of the Company’s financial structure.

FUNDING DEBT FINANCE
View Analyst & Ambassador Comments
Go to original news
Dec 14,2015

Novo Nordisk and IBM partner to build diabetes care solutions on the Watson Health Cloud

Novo Nordisk and IBM Watson Health today announced that the two companies will work together to create diabetes solutions built on the Watson Health Cloud. The agreement combines Novo Nordisk's deep understanding of diabetes with IBM's leadership in cognitive computing. The companies will explore possibilities for improved diabetes care via insights from real-time, real-world evidence of Novo Nordisk diabetes treatments and devices. By harnessing the potential of the Watson Health Cloud, Novo Nordisk aims to further advance its offerings to people living with diabetes and their healthcare professionals.

COLLABORATION PARTNERSHIP

#r&d

View Analyst & Ambassador Comments
Go to original news
Sep 09,2014

Glen Tullman Launches Livongo Health to Empower Consumers with Chronic Conditions to Live Better, Beginning with Diabetes

 Livongo Health™, a consumer digital health company, launched today with a vision to empower people with chronic conditions to live better through the combined power of technology, real-time personalized information, and support from their chosen care team. The company secured initial funding from 7wire Ventures (run by Tullman and long-time partner Lee Shapiro) and a recent $10 million Series A funding round from General Catalyst Partners. Hemant Taneja, Managing Director at General Catalyst said, "We're excited to partner with Glen and team to help accomplish their mission. We think that companies like Livongo can reduce healthcare costs by $100 billion in diabetes alone."

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Dec 13,2017

Livongo Collaborates with CMS for Advance Digital Health

The new CMS Merit Based Incentive Program (MIPS) Improvement Activity, entitled “Engage Patients and Families to Guide Improvement in the System of Care,” enables healthcare providers to be reimbursed for the remote monitoring, review, and interpretation of patient generated health data (PGHD) gathered through clinically endorsed mobile patient engagement applications. Three digital health companies, HealthLoop, Wellpepper, and Livongo – leaders in this fast-growing market – collaborated in working with CMS to raise awareness of how PGHD and digital patient engagement tools can play critical roles in improving the quality of care and outcomes for patients. Top executives from the three companies also participated in the CMS PGHD Round Table in Washington, D.C. on December 6 to further the importance and understanding of the value of PGHD in patient care.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 20,2017

One Drop Among First Apps to Integrate Dexcom CGM Data

In case you just so happen to have missed this nugget of news gold, Dexcom opened up their API to the masses — and One Drop was there to snag a spot. In more technical terms: The CGM powerhouse took their API public, enabling third-party developers to pull Dexcom CGM data directly into their apps.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 17,2021

BIOCORP signs a partnership with SocialDiabetes

BIOCORP today announces the signature of new partnerships with Health2Sync and SocialDiabetes, companies headquartered in Taiwan and Spain, respectively. In detail, the platform developed by SocialDiabetes (CE marked and FDA 510K) allows selfmonitoring of insulin doses and offers personalized recommendations to patients. All of the data collected feeds a telemedicine platform using augmented intelligence for physicians and specialized call centers. To date, this platform is used by 250,000 patients with diabetes, mainly in Spain, Mexico, Colombia and Chile. Patients using these digital solutions will be able to automatically synchronize the data recorded by their Mallya sensor, thus benefiting from a complete monitoring offer combining glycemic data analysis and insulin dose feedback.

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 06,2023

Fitterfly presents outcomes from Digital Therapeutics Platform at 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2023), Germany

Fitterfly's first presentation focused on how their Digital Therapeutics solutions were able to benefit the participants through use of CGM-led behavior change, and personalized lifestyle changes during the 90-day program. Study data included 145 patients who were put on a CGM device for 14 days and then received personalised coaching based on their glycemic responses for next 11 weeks. The study showed 10% improvement in Time in Range (from 66% to 72%) within 14 days and 1% reduction in HbA1c from a baseline of 8.1% in 3 months. This was also accompanied by an average of 2.3 kg of weight loss.

CLINICAL STUDY

#cgm

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 02,2023

Bigfoot Biomedical Receives FDA Clearance for Bigfoot Unity® Android App for People Living with Insulin-Requiring Diabetes

Bigfoot Biomedical today announced the U.S. Food and Drug Administration has issued 510(k) clearance for the Android version of the Bigfoot Unity® Mobile App, a necessary component of the Bigfoot Unity® Diabetes Management System. The Bigfoot Unity System is the first and only FDA-cleared smart injection system that turns continuous glucose management (CGM) data into insulin dosing advice displayed right on the pen cap for people using multiple daily injection therapy. “Most Bigfoot Unity users live with type 2 diabetes and are part of a demographic that is even more likely to use Android devices than the general U.S. population," said Jeffrey Brewer, CEO of Bigfoot Biomedical.

REGULATORY FDA

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 02,2023

Expanded Medicare coverage for CGM to go into effect next month

The Centers for Medicare & Medicaid Services today published a final local coverage determination (LCD) expanding coverage for continuous glucose monitors (CGMs). New, expanded coverage of CGMs under Medicare go into effect in April. CMS first published the local coverage determination (LCD) modifying coverage criteria for CGMs in October. The modification includes people with diabetes who receive insulin treatment or have a history of problematic hypoglycemia. The proposal eliminates the requirement for frequent adjustments of the patient’s insulin treatment regimen. The finalized version changed some language on the criteria. It amended the line saying “the beneficiary is insulin-treated with at least one daily administration of insulin” to, simply, “the beneficiary is insulin-treated.” According to BTIG analyst Marie Thibault, the decision increases access for approximately 1.5 million people using basal-only treatment in the U.S. covered by Medicare. That could expand to between 3 million and 4 million, she said, as U.S. commercial payors follow suit.

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES